Evidence map›Paper›PMID 31686745›Full record

ArticleJournal of obstetrics and gynaecology of India2019

NT-proBNP: A Useful Biochemical Marker for Prognosis in Rh-Isoimmunized Pregnancies.

Vikas Yadav, Dipika Deka, Sharma Aparna, Vatsla Dadhwal

Open access · greenAbstract read
In one paragraph

Article in Journal of obstetrics and gynaecology of India, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vikas YadavDepartment of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, 110029 India.
Dipika DekaDepartment of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, 110029 India.
Sharma AparnaDepartment of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, 110029 India.
Vatsla DadhwalDepartment of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, 110029 India.
All India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRh incompatibility sometimes results in life-threatening conditions in fetus like severe anemia and jaundice, leading to kernicterus and even death. Even after an uneventful intrauterine transfusion (IUT), fetus may not survive despite correction of the fetal anemia. Finding appropriate markers may help in determining the prognosis of such cases. The N-terminal prohormone of brain natriuretic peptide (NT-proBNP) suggests some degree of heart failure.

objectivePresent study was planned to evaluate its role in predicting the outcome of fetus in Rh-isoimmunized pregnant woman.

methodsThis prospective study consisted of total 40 pregnant patients: 10 pregnant Rh-isoimmunized women with hydropic fetuses, 10 with non-hydropic fetuses and 20 control group. If the MCA-PSV was > 1.5 MOM, cord blood sampling and IUT was done and sent for fetal hematocrit and NT-proBNP.

resultsThe levels of NT-proBNP at various periods of gestation in hydropic, non-hydropic and control group fetuses showed positive correlation with the degree of fetal anemia.

conclusionCorrelation of high levels of NT-proBNP to fetal anemia proves that hydrops fetalis is probably due to progressive high cardiac output myocardial failure, increased capillary permeability and perhaps reduced coronary flow.

Indexed as

Heart failureHydropsNT-proBNPRh incompatibility

Identifiers

PMID31686745
PMCPMC6801230
OpenAlexW2895472950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.